Biochemistry (Moscow)

, Volume 80, Issue 1, pp 113–119 | Cite as

PEG-chitosan and glycol-chitosan for improvement of biopharmaceutical properties of recombinant L-asparaginase from Erwinia carotovora

  • K. V. Sukhoverkov
  • E. V. KudryashovaEmail author


Conjugation with the new branched copolymers, PEG-chitosan and glycol-chitosan, is suggested to improve the therapeutic properties of L-asparaginase from Erwinia carotovora (EwA). The structure and composition of such conjugates were optimized for maximal catalytic efficiency (k cat/K M) under physiological conditions, yielding improvement by a factor of 3–6 compared to the native enzyme. This effect is attributed mainly to the shift of pH activity profile towards lower pH values due to the polycationic nature of the copolymer. The thermostability of EwA conjugates was also considerably improved. Chito-PEGylation, similarly to PEGylation, can be expected to improve pharmacokinetic properties and to reduce immunogenicity of this medically relevant enzyme. It is worth mentioning that a new versatile approach based on IR spectroscopy has been developed to determine PEG-chitosan copolymer composition as well as composition of copolymer-enzyme conjugates. The proposed analytic method is “reagent-free” and allows fast and reliable determination of parameters of interest from the single IR spectrum in contrast to laborious and unreliable methods based on polymer free amino group titration with TNBS and OPA.

Key words

recombinant L-asparaginase branched copolymers PEG-chitosan activity thermostability FTIR HPLC pH optima 



dimethyl sulfoxide


L-asparaginase from Erwinia carotovora


monomethoxypoly(ethylene glycol)-N-hydroxysuccinimidyl succinate


polyethylene glycol


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ravindranath, Y., Abella, E., Krischer, J. P., Wiley, J., Inoue, S., Harris, M., Chauvenet, A., Alvarado, C. S., Dubowy, R., and Ritchey, A. K. (1992) Acute myeloid leukemia (AML) in Down’s syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498, Blood, 80, 2210–2214.PubMedGoogle Scholar
  2. 2.
    Pui, C. H., and Evans, W. E. (2006) Treatment of childhood acute lymphoblastic leukemia, N. Engl. J. Med., 354, 166–178.PubMedCrossRefGoogle Scholar
  3. 3.
    Redaelli, A., Laskin, B. L., Stephens, J. M., Botteman, M. F., and Pashos, C. L. (2005) A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL), Eur. J. Cancer Care, 14, 53–62.CrossRefGoogle Scholar
  4. 4.
    Billett, A. L., Carls, A., Gelber, R. D., and Sallan, S. E. (1992) Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase, Cancer, 70, 201–206.PubMedCrossRefGoogle Scholar
  5. 5.
    Uren, J. R., and Handschumacher, R. E. (1977) Enzyme therapy, in Cancer: A Comprehensive Treatise (Becker, F. F., ed.) Plenum Press, N. Y., Vol. 5, pp. 487–557.Google Scholar
  6. 6.
    Papageorgiou, A. C., Posypanova, G. A., Andersson, C. S., Sokolov, N. N., and Krasotkina, J. (2008) Structural and functional insights into Erwinia carotovora L-asparaginase, FEBS J., 17, 4306–4316.CrossRefGoogle Scholar
  7. 7.
    Kuchumova, A. V., Krasotkina, Yu. V., Khasigov, P. Z., and Sokolov, N. N. (2007) PEGylation of the recombinant asparaginase from Erwinia carotovora by polyethylene glycol 5000, Biomed. Khim., 53, 107–111.PubMedGoogle Scholar
  8. 8.
    Mozhaev, V. V., Kudryashova, E. V., Efremova, N. V., and Topchieva, I. N. (1996) Stability of chymotrypsin conjugated with PEGs and proxanols at high temperature and in water-cosolvent mixtures, Biotechnol. Techniq., 10, 849–854.CrossRefGoogle Scholar
  9. 9.
    Soares, A. L., Guimaraes, G. M., Polakiewicz, B., de Moraes Pitombo, R. N., and Abrahao-Neto, J. (2002) Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase, Int. J. Pharm., 237, 163–170.PubMedCrossRefGoogle Scholar
  10. 10.
    Dinndorf, P. A., Gootenberg, J., Cohen, M. H., Keegan, P., and Pazdur, R. (2007) FDA drug approval summary: pegaspargase (Oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL), Oncologist, 12, 991–998.PubMedCrossRefGoogle Scholar
  11. 11.
    Kudryashova, E. V., Zorov, I. N., Vasilyeva, I. V., Sinitsin, A. P., and Levashov, A. V. (2009) Stabilization of alkaline proteinase and cellulases by complex formation with chitosan, Bioorg. Khim., 35, 1–8.Google Scholar
  12. 12.
    Lin, W. J., and Chen, M. H. (2007) Synthesis of multifunctional chitosan with galactose as a targeting ligand for glycoprotein receptor, Carbohydr. Polym., 67, 474–480.CrossRefGoogle Scholar
  13. 13.
    Sokolov, N. N., Eldarov, M. A., Sidoruk, K. V., Zhgun, A. A., Borisova, A. A., Aleksandrova, S. S., Omelyanyuk, N. M., Bogush, V. G., Krasotkina, Yu. V., Gervasiyev, Yu. V., Pokrovskaya, M. V., Sokov, B. N., Berezov, T. T., Skryabin, K. G., and Archakov, A. I. (2005) Development of antitumor preparation of the recombinant L-asparaginase from Erwinia carotovora, Mol. Med., 1, 45–53.Google Scholar
  14. 14.
    Borisova, A. A., Eldarov, M. A., Zhgun, A. A., Aleksandrova, S. S., Omelyanyuk, N. M., Sokov, B. N., Berezov, T. T., and Sokolov, N. N. (2003) Isolation, purification and some properties of the recombinant L-asparaginase from Erwinia carotovora expressed in E. coli cells, Biomed. Khim., 49, 502–507.PubMedGoogle Scholar
  15. 15.
    Karasev, V. S., Bochkova, O. P., Chugunov, A. M., MelikNubarov, N. S., Grozdova, I. D., Chernovskaya, T. V., Denisov, L. A., Rudenko, E. G., Morozova, E. L., Bogush, V. G., Sidoruk, K. V., Koltun, I. O., Skatova, G. E., Abakumova, O. Yu., Podobed, O. V., and Sokolov, N. N. (2010) A method for obtaining the substance of recombinant L-asparaginase from E. carotovora, RF Patent for Invention No. 2441914.Google Scholar
  16. 16.
    Kudryashova, E. V., Sukhoverkov, K. V., and Sokolov, N. N. (2014) Application of copolymers of branched architecture on the basis of PEG-chitosan for regulation of the catalytic properties of enzyme preparation of medical purpose by the example of the new highly efficient recombinant preparation of L-asparaginase from Erwinia carotovora, Biomed. Khim., 60, 16–27.Google Scholar
  17. 17.
    Kudryashova, E. V., Suhoverkov, K. V., and Sokolov, N. N. (2014) Application of PEG-chitosan copolymers for regulation of catalytic properties of enzyme preparations for medical application using recombinant Erwinia carotovora L-asparaginase as an example, Biochemistry (Moscow), Suppl. Ser. B: Biomed. Chem., 8, 252–259.CrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2015

Authors and Affiliations

  1. 1.Chemical FacultyLomonosov Moscow State UniversityMoscowRussia

Personalised recommendations